Chongqing Boteng Pharmaceutical Technology Co., Ltd.

Main purpose of study: According to the provisions of relevant bioequivalence test, dapagliflozin tablets (trade name: FORXIGA®, specification: 10 mg) with AstraZeneca AB as the licensee were selected as the reference preparation, and the test preparation dapagliflozin tablets (specification: 10 mg) produced and provided by Chongqing Boteng Pharmaceutical Co., Ltd. were subjected to human bioequivalence test under fasting and postprandial administration conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose of study: To observe the safety of oral administration of the test preparation dapagliflozin tablets (specification: 10 mg) and the reference preparation dapagliflozin tablets (trade name: FORXIGA®, specification: 10 mg) by healthy subjects.

Main research purpose: According to the relevant provisions of bioequivalence test, the empagliflozin metformin sustained-release tablets (trade name: Synjardy® XR, specification: 25mg/1000mg) produced by Patheon Pharmaceuticals Inc. and licensed by Boehringer Ingelheim Pharmaceuticals, Inc. were selected as the reference preparation, and the test preparation empagliflozin metformin sustained-release tablets (specification: 25mg/1000mg) provided by Chongqing Boteng Pharmaceutical Co., Ltd. were subjected to human bioequivalence test for fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary study objective: To observe the safety of oral administration of the test preparation empagliflozin metformin sustained-release tablets (specification: 25mg/1000mg) and the reference preparation empagliflozin metformin sustained-release tablets (trade name: Synjardy® XR, specification: 25mg/1000mg) to healthy volunteers.

This is a bioequivalence trial, with Sanofi-Aventis certified hydroxychloroquine sulfate tablets (trade name: PLAQUENIL®, specification: 0.2g) as the reference preparation, and hydroxychloroquine sulfate tablets (specification: 0.2g) produced by Chongqing Boteng Pharmaceutical Co., Ltd. as the test preparation. A single-center, randomized, open, two-preparation, single-dose, single-period, parallel design trial was used to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions.